Both were associated with longer progression-free survival after CRT , and mutant IDH was associated with longer overall survival ( 9.4 v 5.7 years ; hazard ratio [ HR ] , 0.59 ; 95 % CI , 0.40 to 0.86 ; P = .006 ) .